Soligenix wins $1.5M NIAID award to support COVID-19, Ebola vaccine development

© Shutterstock The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.5 million grant to Soligenix, Inc. last week to aid manufacture, formulation, and characterization of COVID-19 and ebola virus disease vaccine candidates. All will be pursued in conjunction with the CoVaccine HT adjuvant, and the money will likewise...

Read Full Story

If the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com

Christopher Schaber CoVaccine NIAID National Institute of Allergy and Infectious Diseases SBIR Soligenix